Clinical Trials Logo

Clinical Trial Summary

2019 coronavirus disease (Covid-19) is a virus that emerged in Wuhan, China in late 2019, spread all over the world in a short time and causes severe acute respiratory syndrome and pneumonia. The World Health Organization classified the COVID-19 outbreak as an "international public health emergency" on January 30 and declared a global epidemic (pandemic) on March 11, 2020, due to the rapid spread of the virus all over the world. speed in the number of cases and deaths. Covidien-19 first cases were reported in Turkey on 10 March 2020 and the number of cases has risen steadily. The total number of COVID-19 cases worldwide on 31.01.2021; It was reported to be 101,917,147 and the total number of deaths was 2,205,515 ( Considering that the number of cases is constantly increasing, it is obvious that hospitals will not meet the entire epidemic burden. During this period, home care has emerged as an alternative way to effectively alleviate the epidemic burden. Home healthcare during the COVID-19 pandemic; Four roles have stood out: home diagnosis, follow-up, treatment, and care. Protective measures for home isolation of Covid-19 patients are the current method used to prevent the spread of cases. Possible or definite cases that do not have an indication for hospitalization, have a mild clinic and do not accompany severe chronic disease that may lead to a severe course of covid-19 are followed at home until their symptoms improve. In addition, patients who are hospitalized and meet discharge criteria can complete their recovery processes at home. Isolation is terminated on the 14th day at the earliest following the improvement of symptoms in patients who are followed at home. Reducing the contact of people, isolating certain and suspicious cases and effective use of personal protective equipment play an important role in combating the epidemic. It is thought that the training that COVID-19 cases to be followed up and treated at home will be effective in drug compliance, symptom management and quality of life will be effective in the management of the disease. According to the results of the PCR (Polymerase Chain Reaction) test and Thorax CT (Thorax computed tomography) test performed by the Zonguldak Provincial Health Directorate Public Health Directorate and by the radiation teams, U07.3 (Covid-19 laboratory test positive), J12.9 (Viral Pneumonia, Undefined-Covid-19 laboratory test negative and diagnosed according to Thorax CT result) and J12.8 (Patients diagnosed with Viral Pneumonia-Covid-19 laboratory test negative and Thorax CT result) diagnosed with ICD coded Covid-19 and Zonguldak Public It is planned to create patients who are recommended to be followed up and treated at home by the Presidency of Health.

Clinical Trial Description

G power analysis program was used to determine the sample size. The research will be conducted with two groups, one intervention group and one control group. With professional support in calculating the sample size of the study, the sample size was found to be 128 (64 intervention, 64 control), calculated at a 5% margin of error and a 95% confidence interval. Participants who meet the inclusion criteria and agree to participate in the study will be randomly assigned to the intervention and control groups. DATA COLLECTION TOOLS - Patient information form - Memorial Symptom Rating Scale - Covid-19 Symptom Assessment Inventory - Morisky Adaptation Scale (Muö) - World Health Organization Quality of Life Inventory Short Form Turkish Version - E-Health literacy scale - Opinion Form Regarding the Web Based Training Program - DISCERN Guide (Expert Opinions) - Website Content Evaluation Form (Expert Opinions) ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04824469
Study type Interventional
Source Eskisehir Osmangazi University
Contact Ebru Arslan Özdemir, PhD Student
Phone +90 531 420 96 53
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 2021
Completion date June 2022

See also
  Status Clinical Trial Phase
Suspended NCT04394884 - Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Active, not recruiting NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Recruiting NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Recruiting NCT04357990 - Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19 N/A
Recruiting NCT04528901 - Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
Active, not recruiting NCT04527471 - Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT04661462 - Health After Covid-19 in Tyrol
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Recruiting NCT04532931 - COVID-19 Treatment in South Africa Phase 2
Recruiting NCT04526054 - Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients N/A
Recruiting NCT04757857 - COVID-19 Antithrombotic Rivaroxaban Evaluation Phase 4
Recruiting NCT04578158 - Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19 Phase 3
Active, not recruiting NCT04552366 - A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Phase 1
Enrolling by invitation NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Recruiting NCT04582214 - Oscillation and Lung Expansion Therapy in Patients With COVID-19 N/A
Recruiting NCT04583995 - A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom Phase 3